KIN Kindred Biosciences Inc

Price (delayed)

$9.19

Market cap

$416.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.21

Enterprise value

$426.45M

Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe ...

Highlights
The quick ratio has soared by 120% YoY and by 35% from the previous quarter
The company's EPS has surged by 88% YoY and by 62% QoQ
Kindred Biosciences's debt has increased by 3.7% YoY

Key stats

What are the main financial stats of KIN
Market
Shares outstanding
45.27M
Market cap
$416.06M
Enterprise value
$426.45M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.55
Price to sales (P/S)
8.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.7
Earnings
Revenue
$43.96M
EBIT
-$8.2M
EBITDA
-$3.38M
Free cash flow
-$4.55M
Per share
EPS
-$0.21
Free cash flow per share
-$0.11
Book value per share
$2.02
Revenue per share
$1.07
TBVPS
$2.68
Balance sheet
Total assets
$109.98M
Total liabilities
$26.19M
Debt
$23.3M
Equity
$83.79M
Working capital
$72.54M
Liquidity
Debt to equity
0.28
Current ratio
12.07
Quick ratio
11.58
Net debt/EBITDA
-3.08
Margins
EBITDA margin
-7.7%
Gross margin
96.3%
Net margin
-20%
Operating margin
-15.3%
Efficiency
Return on assets
-8.2%
Return on equity
-11.2%
Return on invested capital
-7.7%
Return on capital employed
-7.9%
Return on sales
-18.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KIN stock price

How has the Kindred Biosciences stock price performed over time
Intraday
0%
1 week
44.5%
1 month
94.29%
1 year
115.22%
YTD
113.23%
QTD
84.91%

Financial performance

How have Kindred Biosciences's revenue and profit performed over time
Revenue
$43.96M
Gross profit
$42.32M
Operating income
-$6.74M
Net income
-$8.78M
Gross margin
96.3%
Net margin
-20%
Kindred Biosciences's net margin has soared by 99% YoY and by 61% from the previous quarter
The operating margin has surged by 99% year-on-year and by 68% since the previous quarter
The operating income has surged by 90% year-on-year and by 66% since the previous quarter
KIN's net income has soared by 87% YoY and by 60% from the previous quarter

Growth

What is Kindred Biosciences's growth rate over time

Valuation

What is Kindred Biosciences stock price valuation
P/E
N/A
P/B
4.55
P/S
8.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.7
The company's EPS has surged by 88% YoY and by 62% QoQ
KIN's price to book (P/B) is 98% higher than its last 4 quarters average of 2.3 and 69% higher than its 5-year quarterly average of 2.7
The equity has increased by 38% year-on-year and by 24% since the previous quarter
The price to sales (P/S) is 105% more than the last 4 quarters average of 4.2
Kindred Biosciences's revenue has increased by 4.3% QoQ

Efficiency

How efficient is Kindred Biosciences business performance
The company's return on sales has surged by 99% YoY and by 64% QoQ
Kindred Biosciences's ROIC has soared by 89% YoY and by 64% from the previous quarter
Kindred Biosciences's return on equity has surged by 86% YoY and by 63% QoQ
Kindred Biosciences's return on assets has surged by 86% YoY and by 62% QoQ

Dividends

What is KIN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KIN.

Financial health

How did Kindred Biosciences financials performed over time
The quick ratio has soared by 120% YoY and by 35% from the previous quarter
The current ratio has soared by 111% YoY and by 33% from the previous quarter
Kindred Biosciences's debt is 72% less than its equity
The equity has increased by 38% year-on-year and by 24% since the previous quarter
Kindred Biosciences's debt to equity has decreased by 24% YoY and by 20% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.